Inflammatory mediators in skin and wound tissue

Inflammatory mediators in skin and wound tissue represent a heterogeneous collection of proteins and lipids that regulate the cutaneous response to injury and pathogens (StatPearls, 2023). This group includes pro-inflammatory cytokines (e.g., TNF-alpha, IL-1 beta), chemokines (e.g., CXCL8), and lipid-derived mediators like prostaglandins, which collectively initiate and sustain the inflammatory phase of wound healing (NCBI, 2022). In healthy tissue, these mediators are transiently expressed to facilitate debris clearance and initiate repair; however, their chronic elevation is a primary driver of pathological states such as diabetic foot ulcers and psoriasis (Nature Reviews Disease Primers, 2022). Therapeutic targeting of these mediators—via monoclonal antibodies, small molecule inhibitors, or topical steroids—aims to resolve chronic inflammation and restore the tissue's regenerative capacity (Journal of Investigative Dermatology, 2021). Furthermore, the balance between pro-inflammatory and anti-inflammatory mediators is crucial for successful tissue remodeling and the prevention of excessive scarring (PubMed, 2020). Because this term describes a broad physiological environment rather than a discrete molecular entity, it serves as a functional category rather than a specific, single therapeutic target.

Other names

Skin inflammatory mediatorsWound cytokinesPro-inflammatory mediators in skinCutaneous inflammatory environment

The mechanism of action involves the antagonism of specific pro-inflammatory cytokines (e.g., TNF-alpha, IL-17) or the inhibition of enzymes like cyclooxygenase (COX) to reduce the production of inflammatory prostaglandins, thereby dampening the immune response and allowing the wound to progress to the proliferative and remodeling phases of healing.